Paroxysmal nocturnal haemoglobinuria at Oslo University Hospital 2000–2010

BACKGROUND Paroxysmal nocturnal haemoglobinuria (PNH) is a rare haematological disease characterised by chronic haemolysis, pancytopenia and venous thrombosis. The condition is attributable to a lack of control of complement attack on erythrocytes, platelets and leucocytes, and can be diagnosed by flow cytometry. In this quality assurance study, we have reviewed information from the medical records of all patients tested for PNH using flow cytometry at our laboratory over a ten-year period.

MATERIAL AND METHOD In the period 2000–2010 a total of 28 patients were tested for PNH using flow cytometry at the Department of Immunology and Transfusion Medicine, Oslo University Hospital. We have reviewed the results of these examinations retrospectively together with information from medical records and transfusion data for the patients concerned.

RESULTS Flow cytometry identified 22 patients with PNH: four with classic disease and 18 with PNH secondary to another bone marrow disease. Five patients had atypical thrombosis. Seventeen patients received anti-thymocyte globulin or drug treatment; of these, six recovered from their bone marrow disease, while six died and five had long-term transfusion requirements. Five patients with life-threatening bone marrow disease underwent allogeneic stem cell transplantation, three of whom died. Six of 22 patients received eculizumab; the need for transfusion has been reduced or eliminated in three patients treated with eculizumab over a longer period.

INTERPRETATION Flow cytometry identified PNH in a majority of patients from whom we obtained samples. Most patients had a PNH clone secondary to bone marrow failure. Atypical thrombosis should be borne in mind as an indication for the test. Treatment with eculizumab is relevant for selected patients with PNH.

The rare disease paroxysmal nocturnal haemoglobinuria (PNH) has an estimated incidence of 1.3 cases per million population per year (1). Patients are classified as either classic PNH (without other bone marrow disease), secondary PNH (associated with bone marrow diseases such as aplastic anaemia and myelodysplastic syndrome (MDS)) or subclinical PNH (associated with bone marrow disease) (2).

PNH is caused by a mutation in the gene phosphatidylinositol glycan, class A (PIG-A) in haematopoietic stem cells. The mutation leads to defective synthesis of the glycosphatidylinositol (GPI) anchor. PNH cells lack proteins that normally bind to the membrane using this anchor, including CD55 and CD59. These two proteins protect cells against complement attack. Absence of the GPI anchor may give PNH cells a survival advantage by rendering them resistant to apoptosis and immunotherapy, thereby enabling PNH clones to become established in the bone marrow and cause disease (3). Complement normally undergoes continual activation via the alternative activation pathway. In healthy individuals this is of no consequence, but in patients with PNH, complement activation leads to haemolysis. The haemoglobin that is released binds nitric oxide (NO), thereby affecting components such as platelets and smooth muscle (4).

Classic PNH is a chronic systemic disease with high mortality (approximately 35% 5-year mortality), but spontaneous recovery after several years of illness is seen in about 15% of cases (5). The disease affects all age groups. The main clinical symptoms are the result of unrestrained complement attack on the patient’s own blood cells (6, 7). Classic PNH manifests clinically with chronic intravascular haemolysis, pancytopenia and recurrent venous thrombosis. The condition is often neither paroxysmal nor nocturnal, but is characterised by continual haemolysis – even when symptoms are absent (8). Haemoglobinuria is not always present (2).

PNH has been featured previously in the Journal of the Norwegian Medical Association (9, 10). Until around 2000, the disease was diagnosed by means of the sucrose haemolysis test and Ham’s test on the basis of complement activation by low ionic strength and low pH, respectively. However, these erythrocyte-based tests can give false negatives after extensive haemolysis, after transfusion and when the dominant PNH population consists of leucocytes. Diagnostic flow
Flow cytometry is sensitive and can identify pathological PNH populations more effectively than the aforementioned tests (10, 11). Flow cytometry detects deficient expression of CD55 and CD59 on the surface of erythrocytes, monocytes and granulocytes, and can reveal PNH clones that constitute only 0.3% of the total cells (10). The use of flow cytometry will also reveal cases of secondary PNH with aplastic anaemia and myelodysplastic syndrome, often in patients who do not have signs of haemolysis (subclinical PNH) (3). In Norway, this method was recommended over the other tests as early as 1999 (10), and it has been used preferentially ever since. In recent years, diagnostics have been further improved through the combination of antibodies with a fluorochrome-labelled molecule (FLAER) that binds to the GPI anchor (12).

The treatment of PNH has been symptomatic – with hydration, pain relief and transfusions in haemolytic crises, and otherwise with iron replacement and anticoagulation therapy. Immunosuppressive therapy is used in secondary PNH (9). Allogeneic stem cell transplantation can provide a permanent cure, but is not first-line therapy because of significant treatment-related morbidity and mortality (13). A humanised monoclonal antibody (eculizumab) against complement protein C5, which prevents formation of the terminal complement complex, has shown good results (8). Eculizumab reduces haemolysis, transfusion requirements, thromboembolic events and mortality, and is also well-tolerated (14, 15). The recently published Norwegian guidelines for diagnosis and treatment of PNH (16) recommend eculizumab for selected patients.

In this article, we describe subtypes, course and treatment of PNH based on a review of the medical records of all patients who were tested for the disease using flow cytometry at the Department of Immunology and Transfusion Medicine, Section for Immunohaematology, Oslo University Hospital over a 10-year period.

Material and method

Patients
The dataset consists of patients who were tested for PNH using flow cytometry between February 2000 and September 2010, when we were responsible for PNH testing in the Southern and Eastern Norway Regional Health Authority. Five of the patients are from other health authorities because Oslo University Hospital is responsible for stem cell transplantations across several health regions. Three of the patients have been described previously (9).

Diagnostic method
Flow cytometry was used for diagnosis throughout the entire period and has been described in detail previously (10). A test was interpreted as positive if the PNH clone(s) made up 1% or more of the cell population examined, with absence of expression of CD55 and/or CD59 in at least two cell populations (Figure 1). We adjusted the clonal size for erythrocytes if the patient had received an erythrocyte transfusion in the last three months.

Variables
Medical and transfusion records were obtained between February 2012 and February 2013 by contacting the referring doctor and blood banks at each of the hospitals. We reviewed the records and noted the referral diagnosis, relevant blood-test results at the time of diagnosis and subsequently, comorbidities and disease course. We also recorded treatment, outcome, follow-up and the results of post-treatment blood tests. Data from the blood banks was recorded as the number of transfused erythrocyte concentrates. All data entry from the medical records was performed by a single individual (LSHN). On the basis of flow cytometric analysis and clinical data from the medical records, patients were classified (LSHN) as classic PNH (chronic haemolysis and pancytopenia with no other bone marrow disease), secondary PNH associated with bone marrow disease, and subclinical PNH (without haemolysis) associated with bone marrow disease (2). For three patients, medical records were incomplete. Two of these did not have PNH. The third patient completed treatment in 2002 and has been included in the dataset with observational data up to 2006.

Data were processed using Excel software (Microsoft Office 2007).

Ethics
The study was approved by the Data Protection Officer at Oslo University Hospital (2011/20340).

Results

Indications
A total of 28 patients, 14 women and 14 men, were tested for PNH using flow cytometry. Indication for testing/referral diagnosis is shown in Table 1.
Diagnostics

We received 41 blood samples (1–5 samples per patient). In all, 23 patients were from the Southern and Eastern Norway Regional Health Authority and five were from other regions. Flow cytometry revealed PNH in 22 of 28 patients, 10 men and 12 women. Four patients were diagnosed as classic PNH, 12 as secondary PNH and six as subclinical PNH. Median age at diagnosis was 50.5 years (14–79 years), median observation time after diagnosis is 52.5 months (1–365 months).

The diagnosis was disproved in four patients, while two were excluded from the dataset due to uncertainty around the diagnosis. Of the 22 patients with PNH, four had previously been investigated with Ham’s test, and three of them had tested negative.

Complications

Thromboembolic episodes were recorded in five patients, including two with classic PNH and three with secondary PNH. There were reports of venous thrombosis of the lower extremities and in the splanchnic area/“stomach area”, portal vein thrombosis/Budd-Chiari syndrome, pulmonary embolism and splenic vein thrombosis. Haemolytic crises (abdominal pain and signs of massive intravascular haemolysis) were described in one patient, while two others showed renal failure and pulmonary hypertension, respectively.

Transfusion requirements

The number of transfusions received after diagnosis varied greatly (median 74, range 1–445), but there was also marked variation in the length of the observation period (1–365 months). Of 21 patients who were transfused, eight received > 100 erythrocyte concentrates. One patient (with classic PNH) did not require transfusion.

Treatment

Patients with classic PNH received anti-thrombotic therapy (warfarin, low-molecular-weight heparin, aspirin. One patient also received iron supplements and granulocyte colony-stimulating factor, while another received erythropoietin. Iron chelation therapy (deferasirox) was used in only one individual with classic disease. Another patient showed clinical improvement after prednisolone.

A total of ten patients (six with secondary and four with subclinical PNH) were treated with anti-thymocyte globulin (ATG) for bone marrow hypoplasia. Five went into complete remission, three died in the course of treatment, one still needed transfusions after treatment and another developed increasing haemolytic anaemia after a couple of years. Five patients with secondary or subclinical PNH underwent stem cell transplantation, one of whom had previously received ATG. Two of the five who underwent stem cell transplants were cured of their primary disease and PNH, whereas three died.

Six patients were treated with eculizumab, two following ATG. Median duration of eculizumab treatment at the end of data collection was 11 months (range < 1 month to 3.5 years). In three of the patients, treatment was discontinued due to transformation to myelodysplastic syndrome/acute myeloid leukaemia (AML) and bleeding complications. At the time of writing, three patients are being treated with eculizumab. Two have secondary PNH – one no longer has anaemia that requires transfusions, the other has reduced transfusion requirements. PNH arose during investigation of anaemia in pregnancy.

PNH arose during investigation of anaemia in pregnancy.

Discussion

Between 2000 and 2010, a total of 28 patients were tested for PNH using flow cytometry in our department, of whom 22 were found to have the disease. Venous thrombosis was described in five of 16 patients with symptomatic disease (31%). This is comparable with other datasets, in which 33–50% of patients were found to have thrombosis (5, 7), as were three of the nine patients in our previous study (9). Two patients with PNH were diagnosed with chronic myeloproliferative disease (myelofibrosis). PNH associated with chronic myeloproliferative disease is rare, but has been described previously (17).

PNH itself is a rare disease. Despite centralised diagnosis and treatment at a regional level, our dataset is small and firm conclusions cannot be drawn. Our main aim is to remind others of the disease so that as many patients as possible can be identified.

Whereas nine patients with suspected PNH were referred to the Department of Haematology, Oslo University Hospital in the 20 years prior to 2001 (9), in the course of a decade (2000–2010) we received samples from 28 patients and detected PNH clones in 22 of them. The threshold for requesting PNH analysis has probably become lower, and flow cytometry is far more sensitive than Ham’s test (11). Nevertheless, it is surprising that so many patients (79%) tested positive. This may be an indication that too few tests are being requested because PNH is rarely suspected.

Table 1 Indication for requisition of flow cytometric PNH-analysis in 28 patients tested for paroxysmal nocturnal haemoglobinuria using flow cytometry in the Department of Immunology and Transfusion Medicine, Oslo University Hospital, Ullevål, 2000–2010. The table shows referral/principal diagnosis. DAT = direct antoglobulin test

<table>
<thead>
<tr>
<th>Indication</th>
<th>Number of patients</th>
<th>Number with confirmed paroxysmal nocturnal haemoglobinuria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aplastic anaemia/myelodysplastic syndrome without haemolysis</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>Aplastic anaemia/myelodysplastic syndrome with haemolysis</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>DAT-negative haemolytic anaemia</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Chronic myeloproliferative disease</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Paroxysmal nocturnal haemoglobinuria diagnosed with Ham’s test</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>28</strong></td>
<td><strong>22</strong></td>
</tr>
</tbody>
</table>
Since 2010, flow cytometry-based diagnosis of PNH has been improved further by combining even more antibodies with FLAER, a fluorochrome-conjugated (Alexa 488) non-lysing mutated proaerolysin, which binds specifically to GPI in the cell membrane (12).

Only six patients were treated with eculizumab, a monoclonal antibody against complement factor C5. In three patients, the drug probably contributed to improvement, in the other three further treatment was not possible because eculizumab was no longer indicated. It is a weakness of the study that we do not have long-term follow-up data from more patients who have been treated with eculizumab.

New and better methods for the diagnosis and treatment of PNH have improved the prognosis for this population (15). The Norwegian guidelines for diagnosis and treatment of PNH have recently been updated (16), and devote significant space to the use of eculizumab. International studies show that the drug reduces transfusion requirements and improves life expectancy among the most severely affected, and is also well tolerated (14, 15).

C5 deficiency is associated with increased risk of meningitis (Neisseria meningitides) (18). Patients who are to receive eculizumab should therefore be vaccinated against meningococcal disease before the start of treatment. They should also be given phenoxymethylpenicillin for self-treatment and/or a safety information card stating that they should be treated without delay on suspicion of meningococcal disease (19). In Norway, eculizumab is indicated for symptomatic PNH (classic and secondary) with or without haemolysis was the indication of unknown aetiology (9). In our dataset, aplastic anaemia and Budd-Chiari syndrome were complications of PNH with FLAER and multiparameter flow cytometric analysis of paroxysmal nocturnal hemoglobinuria cells in aplastic anaemia (21).

More sensitive diagnostic methods that also reveal secondary/subclinical PNH associated with bone marrow disease have transformed the previous view of the disease as a relatively benign condition (9). The dataset presented here illustrates that this is a serious disease, as larger datasets have shown (5), but also a condition with extensive variation in symptoms and severity.

We wish to thank Knut Liseth at Haukeland University Hospital, Birgitte D. Eiken at Østfold Hospital Fredrikstad and Mari Rinde at Akershus University Hospital for help in obtaining patient records. We are also grateful to the blood banks for data on transfusions and to Annette Vetlesen for fusion data from the Blood Bank of Oslo.

Lise Sofie Haug Nissen-Meyer (born 1970)
MD PhD and specialty registrar in immunology and transfusion medicine. The author has completed the ICMEF form and declares the following conflict of interest: The department received funding from Alexion (manufacturer of eculizumab) for three projects related to PNH in 2009, including the current work.

Geir E. Tjønnfjord (born 1953)
head of department and specialist in internal medicine and in haematological disease. He is a professor of haematology at the Institute of Clinical Medicine, University of Oslo. The author has completed the ICMEF form and declares the following conflict of interest: He has received personal honoraria from Alexion Pharma Nordics, which manufactures eculizumab.

Etzbetha Golobiovska (born 1954)
biomedical laboratory scientist in the Section of Immunohaematology. The author has completed the ICMEF form and declares the following conflict of interest: The department received funding from Alexion (manufacturer of eculizumab) for three projects related to PNH in 2009, including the current work.

Jens Kjeldsen-Kragh (born 1956)
specialist in immunology and transfusion medicine. He was formerly a senior consultant in the Department of Immunology and Transfusion Medicine, Oslo University Hospital, and professor at the University of Oslo. He is now a Senior Consultant Physician in Lund and Chief Scientific Officer at Prophylux Pharma AS in Tromsø. The author has completed the ICMEF form and declares the following conflict of interest: The department received funding from Alexion (manufacturer of eculizumab) for three projects related to PNH in 2009, including the current work.

References


Received 4 April 2014, first revision submitted 22 June 2014, accepted 24 April 2015. Editor: Siri Lunde Strømme.